Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Cabozantinib in RET-Rearranged NSCLC

August 27th 2015

Dual Targeting of BRAF and MEK in NSCLC

August 27th 2015

CNS Activity With Next-Generation ALK Inhibitors

August 27th 2015

Overcoming EGFR Inhibitor Resistance in Non-T790M-Positive NSCLC

August 27th 2015

Impressive Findings for Next-Generation EGFR Inhibitors

August 27th 2015

Upfront EGFR-Targeted Therapy for NSCLC

August 27th 2015

Stephenson Cancer Center Aims for NCI Designation

August 21st 2015

Brentuximab Vedotin Label Expanded, Top-Line Results for CLL, NSCLC, and More

August 21st 2015

Explosion in Next-Generation Agents on Horizon in NSCLC

July 31st 2015

Highly effective next-generation therapies are currently in development for patients with oncogene-driven non–small cell lung cancer, specifically those with alterations in EGFR, ALK, ROS1, NTRK, or a variety of other gene.

Investigational Targeted Therapies for Breast Cancer

July 21st 2015

PARP Inhibitors in Triple-Negative Breast Cancer

July 21st 2015

Anti-HER2 Therapy for Metastatic Breast Cancer

July 21st 2015

PI3K Inhibition in Breast Cancer

July 21st 2015

Overcoming Endocrine Resistance in Breast Cancer

July 21st 2015

CDK4/6 Inhibition in Breast Cancer

July 21st 2015

Advancements in ER-Positive Breast Cancer

July 21st 2015

Guiding Treatment With Molecular Testing in Breast Cancer

July 21st 2015

Coleman Explains New Biomarker for PARP Inhibitors in Ovarian Cancer

July 17th 2015

Robert Coleman, MD, discusses a potential new biomarker for PARP inhibition in ovarian cancer that was examined in the ARIEL2 trial.

Global Perspective on the ASCO Annual Meeting

July 16th 2015

New Agents for Refractory Metastatic Colorectal Cancer

July 16th 2015

NEXT PAGE
PREVIOUS PAGE